Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics (Q36755348)

16 August 2017

1 reference

title

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics (English)

1 reference

16 August 2017

0 references

1 reference

5

John Q Trojanowski

1 reference

16 August 2017

1

Leslie M Shaw

1 reference

16 August 2017

2

Magdalena Korecka

1 reference

16 August 2017

Christopher M Clark

3

1 reference

16 August 2017

Virginia M-Y Lee

series ordinal

4

1 reference

16 August 2017

publication date

9 March 2007

1 reference

Nature Reviews Drug Discovery

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

295-303

1 reference

Protein folding and misfolding

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

The biochemistry of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Molecular Pathways of Neurodegeneration in Parkinson's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Nosology of Parkinson's disease: looking for the way out of a quagmire

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Biomedicine. Parkinson's--divergent causes, convergent mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Diagnosis and treatment of Parkinson disease: molecules to medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Frontotemporal dementia: clinicopathological correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

The cytoskeleton in neurodegenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Advancing drug discovery for Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

{beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Screening for inhibitors of tau polymerization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

CSF markers for incipient Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

The role of biomarkers in clinical trials for Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

The Alzheimer's disease neuroimaging initiative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Platelet APP isoform ratios correlate with declining cognition in AD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Differential Level of Platelet Amyloid beta Precursor Protein Isoforms: An Early Marker for Alzheimer Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Inflammation and Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Increased nuclear DNA oxidation in the brain in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Human kallikrein 6 as a biomarker of alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Serum p97 levels as an aid to identifying Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Cholesterol, A beta and Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

The role of synaptic proteins in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2176

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2176

1 reference

16 August 2017

1 reference